drugset / Trial / NCT04674826
A Trial to Compare the Pharmacokinetics of Tralokinumab in Healthy Subjects
RandomizedCrossoverOpen-labelTreatment
Summary
The purpose of this trial is to compare the pharmacokinetics (PK), safety, tolerability and immunogenicity of a single dose of 300 mg tralokinumab administered as a 1 × X mL subcutaneous (SC) injection with Device A and 2 × Y mL consecutive SC injections with Device B.
Timeline
- Start
- 2021-02-08
- Primary completion
- 2021-12-29
- Completion
- 2021-12-29
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Tralokinumab | Monoclonal antibody | 300 mg | Subcutaneous |
Indications
No indication recorded.